Raymond James Financial’s Corcept Therapeutics CORT Stock Holding History

Raymond James Financial’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.45M	Buy	85,624 +58,084	+211%	+$3.51M	﹤0.01%	2404
2026 Q1	$1.11M	Sell	27,540 -24,534	-47%	-$917K	﹤0.01%	3777
2025 Q4	$1.81M	Sell	52,074 -56,980	-52%	-$4.48M	﹤0.01%	3353
2025 Q3	$9.06M	Buy	109,054 +4,028	+4%	+$291K	﹤0.01%	1999
2025 Q2	$7.71M	Buy	105,026 +27,112	+35%	+$1.97M	﹤0.01%	2069
2025 Q1	$8.9M	Sell	77,914 -161,889	-68%	-$9.85M	﹤0.01%	1903
2024 Q4	$12.1M	Buy	+239,803	New	+$12.6M	﹤0.01%	1688

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's CORT Position: Q2 2026 in Review

Raymond James Financial increased its Corcept Therapeutics (CORT) stake by 211% in Q2 2026, buying an estimated $3.51M and bringing the position to 85,624 shares worth $7.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2404.

Raymond James Financial first reported a position in CORT in Q4 2024 and has held it in 7 quarters since. The position peaked at $12.1M in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Raymond James Financial held 85,624 shares of Corcept Therapeutics worth $7.45M as of Q2 2026.
Raymond James Financial bought 58,084 Corcept Therapeutics shares in Q2 2026, an estimated $3.51M.
Corcept Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2404 holding.
Raymond James Financial first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Corcept Therapeutics position peaked at $12.1M in Q4 2024.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.